Biopharma Ecosystem Competitiveness: Post-COVID Challenges and Opportunities
Biopharma Ecosystem Competitiveness in Global Race
A new EFPIA analysis compares bioph...
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
EMA Validates ENHERTU Breast Cancer Treatment Variation
The European Medicines Agency (EMA) has validated a Type II Variation marketing authorization application for ENHERTU breast cancer treatment, specifically ENHERTU (trast...
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection with SGLT2 Inhibitors
Type 2 Diabetes Guidelines Reshape Initial Treatment
The latest Type 2 Diabetes Guidelines from NICE (National Institute for Health and Care Excellence), published on 18 February 2026 as an update to guideline NG28 ("Type 2 diabe...
Enhancing Safety and Performance: The Role of EU Medical Device Panels
EU Medical Device Panels: Enhancing Safety and Performance Evaluations
EU Medical Device Panels established by the European Medicines Agency (EMA) provide specialized expertise on clinical and performance evaluat...
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
MFN Policy Effectiveness in Countering Freeloading Claims
The MFN policy effectiveness is evident in the coalition letter dated February 12, 2026, which opposes codifying Most-Favored-Nation (MFN) prescription drug pricing b...
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implications for Alzheimer&...
Dutch Health Insurance Rejects Lecanemab Coverage
Zorginstituut Nederland's advisory letter dated 13 February 2026 recommends against including lecanemab (Leqembi®) in the Dutch basic health insurance package, marking a key lecanema...
